NNVC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
NanoViricides, Inc (NNVC) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite a positive analyst rating and potential in its pipeline, the company's weak financial performance, lack of recent news catalysts, and neutral trading sentiment suggest that it is better to hold off on investing until clearer positive signals emerge.
The technical indicators for NNVC show a bearish trend with moving averages (SMA_200 > SMA_20 > SMA_5). The MACD is slightly positive but contracting, and the RSI is neutral at 40.499. The stock is trading below the pivot level of 0.947, with support at 0.871 and resistance at 1.024. Overall, the technicals do not indicate a strong buy signal.
Alliance Global analyst initiated a Buy rating with a $6 price target, citing significant potential for the company's NV-387 drug in Phase 2 trials.
No recent news or significant insider or hedge fund trading activity. The company's financials show declining net income (-42.91% YoY) and EPS (-56.52% YoY), with no revenue growth.
In Q1 2026, the company reported no revenue growth (0% YoY) and a significant drop in net income (-42.91% YoY) and EPS (-56.52% YoY). Gross margin remains at 0%. The financial performance is weak and does not support a strong buy case.
Alliance Global analyst James Molloy initiated coverage with a Buy rating and a $6 price target, highlighting potential for the company's NV-387 drug in Phase 2 trials. However, there are no other recent analyst updates or consensus ratings.
